


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


1-26 (Cancelled)

27 (New). A cell activator comprising a glycosphingolipid having a structure represented by the following formula (1) formula (1)



wherein R^1 represents the following formula (1-1):

formula (1-1)




wherein R^3 represents alkyl or alkenyl and R^4 represents alkyl; and

R² represents hydrogen, or α-galactose, α-glucose, α-mannose, α-glucosamine, β-glucosamine or a combination thereof.


28 (New). A cell activator comprising a glycosphingolipid having a structure represented by the following formula (3):

formula (3)




wherein R⁵ represents R⁵¹, R⁵², R⁵³, R⁵⁴, R⁵⁵, R⁵⁶, R⁵⁷, R⁵⁸, R⁵⁹, R⁷⁰, R⁷¹, R⁷², R⁷³, R⁷⁴, R⁷⁵, R⁷⁶, R⁷⁷, or R⁷⁸; and R⁶ represents hydrogen, R⁶², R⁶³, R⁶⁴, or R⁶⁵:


R⁵¹ :




R⁵² :




R⁵³ :




R⁵⁴:




R⁵⁵:




R⁵⁶:




R⁵⁷:




R⁵⁸:




R⁵⁹:




R⁷⁰:




R⁷¹:




R⁷²:




R⁷³:




R⁷⁴:




R⁷⁵:




R⁷⁶:




R⁷⁷:




R⁷⁸:




R⁶²:




R⁶⁴:



R⁶³:



R⁶⁵:



29 (New). A method of activating NKT cell which comprises administering the cell activator according to claim 27 to a mammal.

30 (New). A method of activating NKT cell which comprises administering the cell activator according to claim 28 to a mammal,

31 (New). A method of accelerating IL-4 production which comprises administering the cell activator according to claim 27 to a mammal.

32 (New). A method of accelerating IL-4 production which comprises administering the cell activator according to claim 28 to a mammal.

33 (New). A method of accelerating IFN- γ production which comprises administering the cell activator according to claim 27 to a mammal.

34 (New). A method of accelerating IFN- γ production which comprises administering the cell activator according to claim 28 to a mammal.

35 (New). A method of activating dendritic cell which comprises administering the cell activator according to claim 27 to a mammal.

36 (New). A method of activating dendritic cell which comprises administering the cell activator to claim 28 to a mammal.

37 (New). A method of accelerating IL-12 production which comprises administering the cell activator according to claim 27 to a mammal.

38 (New). A method of accelerating IL-12 production which comprises administering the cell activator according to claim 28 to a mammal.

39 (New). A method of accelerating IL-10 production which comprises administering the cell activator according to claim 27 to a mammal.

40 (New). A method of accelerating IL-10 production which comprises administering the cell activator according to claim 28 to a mammal.

41 (New). A method of activating NK cell which comprises administering the cell activator according to claim 27 to a mammal.

42 (New). A method of activating NK cell which comprises administering the cell activator according to claim 28 to a mammal.

43 (New). A method for treatment or prophylaxis of tumor comprises administering the cell activator according to claim 27 to a mammal.

44 (New). A method for treatment or prophylaxis of tumor comprises administering the cell activator according to claim 28 to a mammal.

45 (New). A method for treatment or prophylaxis of allergy comprises administering the cell activator according to claim 27 to a mammal.

46 (New). A method for treatment or prophylaxis of allergy comprises administering the cell activator according to claim 28 to a mammal.

47 (New). A method of enhancing resistance to infection which comprises administering the cell activator according to claim 27 to a mammal.

48 (New). A method of enhancing resistance to infection which comprises administering the cell activator according to claim 28 to a mammal.

49 (New). A method of inhibiting viral activity which comprises administering the cell according to claim 27 to a mammal.

50 (New). A method of inhibiting viral activity which comprises administering the cell activator according to claim 28 to a mammal.

51 (New). A method of accelerating IL-6 production which comprises administering the cell activator according to claim 27 to a mammal.

52 (New). A method of accelerating IL-6 production which comprises administering the cell activator according to claim 28 to a mammal.

53 (New). A method of accelerating NO production which comprises administering the cell activator according to claim 27 to a mammal.

54 (New). A method of accelerating NO production which comprises administering the cell activator according to claim 28 to a mammal.